Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Core Insights - Evaxion A/S will present two-year clinical efficacy data from its phase 2 trial of the personalized cancer vaccine EVX-01 at the ESMO Congress 2025 in Berlin [1][3] - EVX-01, developed using Evaxion's AI-Immunology™ platform, is currently being evaluated for advanced melanoma treatment, showing a 69% Overall Response Rate in interim data [2][4] - The phase 2 trial combines EVX-01 with MSD's KEYTRUDA® therapy, tailored to each patient's unique tumor profile [4][6] Company Overview - Evaxion is a clinical-stage TechBio company focused on AI-driven immunotherapies for cancer and infectious diseases [9] - The company utilizes its AI-Immunology™ platform to create personalized vaccines, aiming to enhance immune responses against tumors [6][9] - Evaxion's pipeline includes novel personalized vaccines for oncology and preclinical candidates for bacterial and viral diseases [9] Clinical Trial Details - The phase 2 trial of EVX-01 has shown promising results, with 67% of metastatic melanoma patients achieving objective clinical responses in earlier trials [7] - The upcoming presentation at ESMO will include data on T-cell responses and disease control over two years [5][6] - The trial emphasizes the correlation between AI predictions and immune responses, highlighting the platform's predictive capabilities [2][7]